Enatsu S - Search Results

1

[Pharmacological Effects of CDK4 & 6 Selective Inhibitor Abemaciclib in Hormone Receptor-Positive Breast Cancer].

Tamaki C, Hayashi S, Sato A, Maeda K, Sakaguchi S, Buchanan S, Enatsu S. Tamaki C, et al. Among authors: enatsu s. Gan To Kagaku Ryoho. 2019 Sep;46(9):1405-1411. Gan To Kagaku Ryoho. 2019. PMID: 31530780 Japanese.

2

[Drug interactions in medical oncology].

Ishiguro H, Koshiji M, Morizane T, Taniai H, Enatsu S, Fujimoto T, Nambu Y. Ishiguro H, et al. Among authors: enatsu s. Gan To Kagaku Ryoho. 2009 May;36(5):879-85. Gan To Kagaku Ryoho. 2009. PMID: 19461200 Review. Japanese.

3

[Safety and effectiveness of pemetrexed in patients with non-small cell lung cancer in Japan - analysis of post-marketing surveillance].

Okubo S, Kobayashi N, Taketsuna M, Kaneko N, Enatsu S, Nishiuma S. Okubo S, et al. Among authors: enatsu s. Gan To Kagaku Ryoho. 2014 Apr;41(4):475-81. Gan To Kagaku Ryoho. 2014. PMID: 24743364 Japanese.

4

[Pemetrexed for Treatment of Nonsquamous Non-Small-Cell Lung Cancer].

Omori Y, Enatsu S. Omori Y, et al. Among authors: enatsu s. Gan To Kagaku Ryoho. 2018 Nov;45(11):1609-1613. Gan To Kagaku Ryoho. 2018. PMID: 30449848 Japanese.

5

Patients' preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan.

Omori Y, Enatsu S, Cai Z, Ishiguro H. Omori Y, et al. Among authors: enatsu s. Breast Cancer. 2019 Sep;26(5):652-662. doi: 10.1007/s12282-019-00965-4. Epub 2019 Apr 4. Breast Cancer. 2019. PMID: 30949915 Free PMC article.

6

Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials.

Toi M, Inoue K, Masuda N, Iwata H, Sohn J, Hae Park I, Im SA, Chen SC, Enatsu S, Turner PK, André VAM, Hardebeck MC, Sakaguchi S, Goetz MP, Sledge GW Jr. Toi M, et al. Among authors: enatsu s. Cancer Sci. 2021 Jun;112(6):2381-2392. doi: 10.1111/cas.14877. Epub 2021 May 1. Cancer Sci. 2021. PMID: 33686753 Free PMC article. Clinical Trial.

7

[Exon 19 Deletion and Exon 21 L858R Point Mutation in EGFR Mutation‒Positive Non‒Small Cell Lung Cancer].

Matsui T, Tanizawa Y, Enatsu S. Matsui T, et al. Among authors: enatsu s. Gan To Kagaku Ryoho. 2021 May;48(5):673-676. Gan To Kagaku Ryoho. 2021. PMID: 34006711 Review. Japanese.

8

[Differences between EGFR Exon 19 Deletion and Exon 21 L858R Point Mutation, Frequently Detected EGFR Mutations in Patients with Non-Small Cell Lung Cancer, from a Molecular Biology Viewpoint].

Kohno T, Matsui T, Enatsu S. Kohno T, et al. Among authors: enatsu s. Gan To Kagaku Ryoho. 2021 Dec;48(12):1463-1467. Gan To Kagaku Ryoho. 2021. PMID: 34911913 Review. Japanese.

9

Patients' Preferences for Attributes of Molecular Targeting Therapies for Advanced Non-Small Cell Lung Cancer with EGFR Mutations in Japan-A Discrete-Choice Experiment.

Nakagawa K, Tanizawa Y, Cai Z, Matsui T, Enatsu S. Nakagawa K, et al. Among authors: enatsu s. Gan To Kagaku Ryoho. 2022 Dec;49(12):1329-1338. Gan To Kagaku Ryoho. 2022. PMID: 36539245

10

Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.

Cheng Y, Murakami H, Yang PC, He J, Nakagawa K, Kang JH, Kim JH, Wang X, Enatsu S, Puri T, Orlando M, Yang JC. Cheng Y, et al. Among authors: enatsu s. J Clin Oncol. 2016 Sep 20;34(27):3258-66. doi: 10.1200/JCO.2016.66.9218. Epub 2016 Aug 9. J Clin Oncol. 2016. PMID: 27507876 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

49 results

Search Page

Filters